X4 Pharmaceuticals, Inc (XFOR) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 151 transactions totaling $2.5M, demonstrating a bearish sentiment with -$1.9M in net insider flow. The most recent transaction on Oct 23, 2025 involved a purchase of 86,206 shares valued at $250.0K.
No significant insider buying has been recorded for XFOR in the recent period.
No significant insider selling has been recorded for XFOR in the recent period.
Based on recent SEC filings, insider sentiment for XFOR is bearish with an Insider Alignment Score of 11/100 and a net flow of -$1.9M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at X4 Pharmaceuticals, Inc (XFOR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading XFOR stock, having executed 151 transactions in the past 90 days. The most active insider is Paula Ragan (Executive), who has made 45 transactions totaling $1.1M.
Get notified when executives and directors at XFOR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Oct 23, 2025 | R. Craig Adam | Executive | Purchase | 86,206 | $2.90 | $250.0K | |
| Aug 14, 2025 | Kirske David | Executive | Award | 193,254 | $N/A | $0 | |
| Aug 14, 2025 | R. Craig Adam | Executive | Award | 289,881 | $N/A | $0 | |
| Aug 14, 2025 | Volpone John | Executive | Award | 289,881 | $N/A | $0 | |
| Sep 9, 2024 | Dibiase Mary | Executive | Sale | 2,642 | $0.66 | $1.7K | |
| Jun 10, 2024 | S. Wyzga Michael | Executive | Award | 45,000 | $N/A | $0 | |
| Jun 10, 2024 | Frances Lawton Alison | Executive | Award | 45,000 | $N/A | $0 | |
| Jun 10, 2024 | Woods Keith | Executive | Award | 45,000 | $N/A | $0 | |
| Jun 10, 2024 | Bridger Gary | Executive | Award | 45,000 | $N/A | $0 | |
| Jun 10, 2024 | Stewart Murray | Executive | Award | 45,000 | $N/A | $0 | |
| Jun 10, 2024 | W. J. Mcgirr David | Executive | Award | 45,000 | $N/A | $0 | |
| Jun 10, 2024 | Aliski William | Executive | Award | 45,000 | $N/A | $0 | |
| Jun 10, 2024 | Francoise De Craecker | Executive | Award | 45,000 | $N/A | $0 | |
| Mar 11, 2024 | Dibiase Mary | Executive | Sale | 15,409 | $0.88 | $13.6K | |
| Mar 11, 2024 | S. Mostafa Adam | Executive | Sale | 52,500 | $0.88 | $46.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 87 | $2.2M | 88.3% |
Purchase(P) | 2 | $280.0K | 11.3% |
Payment(F) | 2 | $8.5K | 0.3% |
Award(A) | 60 | $0 | 0.0% |
Insider selling pressure at X4 Pharmaceuticals, Inc has increased, with 19 insiders executing 151 transactions across all time. Total sales of $2.2M significantly outpace purchases of $280.0K, resulting in a net outflow of $1.9M. This selling activity appears largely discretionary, which may warrant closer attention from investors.